NEJM· @NEJM · X·· 4 小时前AI 评分38
AI 导读
一线安贝尼妥单抗联合HB1801对HER2阳性晚期乳腺癌24个月无进展生存期和缓解的影响尚不确定。3期HEALER试验的研究结果在一段新的Quick Take视频中进行了总结。https://nej.md/4iIfcAw
正文
The effect of first-line anbenitamab plus HB1801 on 24-month progression-free survival and response in HER2-positive advanced breast cancer is uncertain. Research findings from the phase 3 HEALER trial are summarized in a new Quick Take video. https://nej.md/4iIfcAw
来源:NEJM · x.com